$PKBK

PARKE BANCORP, INC. (PKBK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FOR IMMEDIATE RELEASE Parke Bancorp, Inc. Appoints Entrepreneur Michael L. Regina to Board of Directors WASHINGTON TOWNSHIP, N.J. — September 24, 2026 — Parke Bancorp, Inc. (NASDAQ: PKBK), the holding company for Parke Bank, today announced the appointment of promine

Original reporting
Published Sep 24, 2026, 7:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 7:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PKBK
Neutral
medium confidence
Mentioned
$PKBK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PKBKNeutralLow
01

Why it matters

The appointment adds real‑estate and fintech experience to the board, potentially shaping loan portfolio strategy.

02

Market read

A routine governance filing with limited immediate trading relevance for PKBK.

03

What to watch

Regulatory environment for community banks and potential impact of new director's real‑estate expertise.

Relevance 6/10Novelty 6/10Timing: filed Sep 24 2026

Background

Parke Bancorp is a NASDAQ‑listed community bank holding company focusing on New Jersey and Charleston markets.

Company-level read

Ticker impact

$PKBKNeutralMedium confidence
Context

SEC Form 8‑K reports appointment of Michael L. Regina to Parke Bancorp's board, a new corporate governance change.

Expected impact

minimal short‑term impact; potential modest upside if governance improves long‑term perception.

Evidence & confidence

Appointment is a routine corporate action for a small‑cap bank; investors typically view such news as low‑impact.

Market effects

Minor relevance to regional community banking sector; no sector‑wide shift.

Limited to New Jersey and South Carolina banking markets.

None

Counterpoint

Board changes can signal upcoming strategic pivots; watch for future announcements on real estate lending.

Key entities

  • Michael L. Regina

    Entrepreneur and co‑founder of Big Sky Enterprises; new board member.

  • Parke Bancorp, Inc.

    Bank holding company (NASDAQ: PKBK).

Related articles

$PKBKHigh

PARKE BANCORP, INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Parke Bancorp, Inc. 601 Delsea Drive, Washington Township, NJ 08080 Contact: Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS Highlights: Net Income: $12.2 m

$PKBKMed

PARKE BANCORP, INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS

PARKE BANCORP, INC. (PKBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_970396.htm EXHIBIT 99.1 ex_970396.htm Exhibit 99.1 Parke Bancorp, Inc. 601 Delsea Drive, Washington Township, NJ 08080 Contact: Vito S. Pantilione, President and CEO Jonathan D. Hill, Senior Vice President and CFO (856) 256-2500 PARKE BANCORP, INC. ANNOUNCES SECOND Q

$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl